Biocon, a pharmaceutical company, has received various approvals and certifications related to its manufacturing facilities and biosimilar products. The USFDA issued observations to its API facility in Visakhapatnam. The European Medicines Agency approved the manufacture of biosimilar Bevacizumab at its drug substance facility in Bengaluru and renewed Good Manufacturing Practice Certificates of Compliance. Biocon's arm also received approval from the EMA for a new mAbs facility in Bengaluru. Additionally, Biogen received marketing authorization from the European Commission for a proposed biosimilar for immune-mediated inflammatory diseases. Biocon Biologics obtained EMA approval to manufacture biosimilar Bevacizumab for cancer treatment.
Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab used in cancer treatment https://t.co/iZx60jlUSL
Biogen is excited to announce that the European Commission (EC) has granted marketing authorization for a proposed biosimilar for treatment of immune-mediated inflammatory diseases. Read more in the news release: https://t.co/1FgP9qr3yE https://t.co/KaR1Bo0DE7
#Biocon arm gets approval from European Medicines Agency for new mAbs facility in Bengaluru.
#Biocon receives approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at drug substance facility in Bengaluru Co also announces that EMA has renewed its Good Manufacturing Practice Certificates of Compliance for its biosimilars manufacturing… https://t.co/0oskvSLcE1
#Biocon: USFDA issues four observations to API facility in Visakhapatnam. The unit was inspected on June 21.